Human Cancer Models Initiative

Next-generation Cancer Models

As part of our pledge to elevate biological models, ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models, including organoids. ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Cancer Models Based on Physiological System:

Coming Soon

Respiratory System

Reproductive System

Musculo-skeletal System

Integumentary System

Excretory System

Circulatory System

What Are Organoids

Organoids are complex, 3D organ-like microtissues composed of multiple differentiated cell types that are structurally organized similar to that found in vivo, with central lumens and other in vivo–like architectural features. Organoids have been described for various tissues including gastric, intestine, cerebrum, optic cup, lung, pituitary, kidney, and liver.

Check out our HCMI Resources to learn more about these and other next-generation models.

Back to top

Advanced Biological Models

Advanced models such as organoids and conditionally reprogrammed cells (CRCs) better capture the tissue architecture and complexity of human tumors than the current models, lending further credibility to your research. To enhance their clinical relevance, the sequence data and patient clinical information for each model is available to the research community.

  • 2D and 3D patient-derived models available
  • Novel models such as organoids available
  • Easy-to-follow culturing protocols
  • Annotated with clinical data
  • Comprehensive genomic information available
  • Fully authenticated, versatile in vitro tools
Back to top

What is the Early Adopter Program?

Don't see the next-generation in vitro model that you need for your experiments? Follow the link below to apply for early access to organoids, conditionally reprogrammed cells, and other novel models for cancer research.

Back to top

Human Cancer Models Initiative (HCMI)

HCMI is an international consortium that is dedicated to generating novel human tumor-derived culture models with associated genomic and clinical data. The HCMI consortium comprises funding agencies and cancer model development institutions. The consortium's funding agencies include the National Cancer Institute (NCI), Cancer Research UK (CRUK), Hubrecht Organoid Technology (HUB), and Wellcome Sanger Institute (WSI). NCI-funded model development institutions include the Broad Institute and the Cold Spring Harbor Laboratory. CRUK and WSI co-fund organoid development in the United Kingdom; CRUK provides the patient samples, while WSI derives and sequences the organoid models. The foundation HUB is a Netherlands-based not-for-profit organization that derives and sequences organoid models. ATCC was selected as the sole distributor for the HCMI models. The generating institutions deposit the models into ATCC, where they are authenticated, expanded, preserved, and made available for global distribution. The HCMI model data is provided as an open source to the research community. 

Back to top

By Tissue

ATCC is continually adding new HCMI models to its collection of better biological models. Use these links to browse these models by of origin.

By Technology

Conditionally Reprogrammed Cells Coming soon!

You can also search HCMI next-generation in vitro models by culture technology or format using the links in this section.

Recommended Products

CellMatrix Basement Membrane Gel
Stem Cell Freezing Media
ROCK Inhibitor Y27632
L-Glutamine Solution, 200 mM

ATCC can provide the gel matrix and other reagents that you need to grow and subculture your HCMI models.